How systemic light chain amyloidosis affects the eyes
Part of Blood & lymphatic, Eyes & vision clinical trials.
This study looks at how systemic light chain amyloidosis, a condition where abnormal proteins build up in organs, may affect your eyes. By comparing eye exams of people with and without the disease, researchers hope to learn more about eye-related changes so they can improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with systemic light chain amyloidosis
- No other serious health problems that could affect the eye exam
- Willing to sign a consent form to participate
- Between 18 and 80 years old
- No eye diseases that have a clear cause, like certain cancers, corneal injury, or severe eye trauma
- No heart failure that limits all physical activity or certain high blood test levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information and eye health data from people who have had cancer treatment, including stem cell transplants. It helps doctors understand how cancer therapies affect the eyes over time.
This trial is a general screening step for people who may have an eye (ocular) condition, or for family members of someone with an eye condition. The goal is to help match you to an eye research study by confirming your situation and whether you can safely participate.
This study looks at whether people with systemic lupus erythematosus (SLE) have early signs of vision problems. Eye tests will be used to check how well you see and if there are any hidden issues in your eyes.
This study is building a detailed database of images and information from people with various eye diseases, especially those involving inflammation or swelling. Researchers will use advanced cameras and tests to better understand these conditions and potentially improve treatments.
This study collects information from people with suspected or confirmed amyloidosis. The goal is to learn more about the condition and improve patient care.
This study follows people with eye conditions (including when the diagnosis is unclear) to learn what causes them and how they change. It may help by giving you closer eye evaluations and contributing knowledge that could improve care for future patients.
Hear when a new Systemic Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.